Abstract: Selective extracorporeal blood disinfection systems and related methods are disclosed. The systems comprise an input tube forming a flowpath for the flow of infected blood. The systems further comprise a disinfection unit comprising a microbicidal light emitting device configured to emit visible light within the range of about 380-425 nm and/or about 500-700 nm, and a treatment flowpath in communication with the input tube that is substantially transparent to the emitted light of the microbicidal light emitting device for receiving at least a portion of the flow of the infected blood therethrough. The microbicidal light emitting device effectuates a dose of the emitted light to the infected blood flowing through the treatment flowpath to disinfect the blood. The systems also comprise an output tube in fluid communication with the treatment flowpath forming a flowpath for the flow of the disinfected blood from the disinfection unit.

Abstract: The present invention is directed to combination pharmacological treatments that induce a prolonged, modest decrease in core body temperature, to the range of ?95° F. to ?98.5° F. (?35° C. to ?36.7° C.) to mitigate and delay the early onset and progression of fatal disease processes associated with premature aging, such as those characteristic of progeria (Hutchinson-Gilford Progeria Syndrome, HGPS), Wiedemann-Rautenstrauch syndrome (neonatal progeroid syndrome), Werner syndrome, and other rare disorders characterized by premature aging, and to prolong the shortened lifespan of children afflicted with these diseases. Short-term chronic administration of the pharmaceutical treatments to a person suffering from mild concussion may also have value in ameliorating neurological damage/symptoms associated with mild concussion. Chronic administration of the pharmacological treatments may also have value in normal human populations or in high-risk human populations.

Abstract: The present invention is directed to combination pharmacological treatments that induce a prolonged, modest decrease in core body temperature, to the range of ?95° F. to ?98.5° F. (?35° C. to ?36.7° C.) to mitigate and delay the early onset and progression of fatal disease processes associated with premature aging, such as those characteristic of progeria (Hutchinson-Gilford Progeria Syndrome, HGPS), Wiedemann-Rautenstrauch syndrome (neonatal progeroid syndrome), Werner syndrome, and other rare disorders characterized by premature aging, and to prolong the shortened lifespan of children afflicted with these diseases. Short-term chronic administration of the pharmaceutical treatments to a person suffering from mild concussion may also have value in ameliorating neurological damage/symptoms associated with mild concussion. Chronic administration of the pharmacological treatments may also have value in normal human populations or in high-risk human populations.

Abstract: The present invention is directed to combination pharmacological treatments that induce a prolonged, modest decrease in core body temperature, to the range of ˜95° F. to ˜98.5° F. (˜35° C. to ˜36.7° C.) to mitigate and delay the early onset and progression of fatal disease processes associated with premature aging, such as those characteristic of progeria (Hutchinson-Gilford Progeria Syndrome, HGPS), Wiedemann-Rautenstrauch syndrome (neonatal progeroid syndrome), Werner syndrome, and other rare disorders characterized by premature aging, and to prolong the shortened lifespan of children afflicted with these diseases. Short-term chronic administration of the pharmaceutical treatments to a person suffering from mild concussion may also have value in ameliorating neurological damage/symptoms associated with mild concussion. Chronic administration of the pharmacological treatments may also have value in normal human populations or in high-risk human populations.

Abstract: The present invention is directed to combination pharmacological treatments that induce a prolonged, modest decrease in core body temperature, to the range of ˜95° F. to ˜98.5° F. (˜35° C. to ˜36.7° C.) to mitigate and delay the early onset and progression of fatal disease processes associated with premature aging, such as those characteristic of progeria (Hutchinson-Gilford Progeria Syndrome, HGPS), Wiedemann-Rautenstrauch syndrome (neonatal progeroid syndrome), Werner syndrome, and other rare disorders characterized by premature aging, and to prolong the shortened lifespan of children afflicted with these diseases. Short-term chronic administration of the pharmaceutical treatments to a person suffering from mild concussion may also have value in ameliorating neurological damage/symptoms associated with mild concussion. Chronic administration of the pharmacological treatments may also have value in normal human populations or in high-risk human populations.

Abstract: The present invention relates to formulations of anti-hypertensive drugs. The present invention includes a modified-release formulation of diltiazem hydrochloride that is suitable for once-daily use and which provides delivery of drug either in the early morning hours, or overnight, so as to blunt the natural rise in blood pressure (BP) and heart rate (HR) in the morning and to reduce the slope of the increase in BP in patients with elevated BP (hypertension).

Abstract: A method for the treatment of spinal cord injury is disclosed. The method involves the administration of a therapeutically effective amount of a defibrinogenating or fibrinolytic agent. In accordance with the principles of the invention, also disclosed are a method for the treatment of neuronal and neurological damage associated with or caused by spinal cord injury, a method for minimizing neuronal and neurological damage associated with spinal cord injury, a method for reducing, limiting, and/or delaying scarring at the site of a spinal cord injury, a method for reducing or limiting the development of spontaneously occurring, post-operative or post-traumatic injury spinal adhesions, a method for educing or limiting the development of spontaneously occurring, post-operative or post-traumatic injury spinal tethering and a method for reducing or limiting the pain associated with arachnoiditis. In a preferred aspect of the disclosed methods, the defibrinogenating agent is ancrod.